aTyr Pharma, Inc. (LIFE)

Get LIFE Alerts
*Delayed - data as of Feb. 5, 2016  -  Find a broker to begin trading LIFE now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
Basic Chart Interactive Chart
Company Headlines Press Releases Market Stream
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Life Technologies (LIFE)

Q4 2012 Earnings Call

February 04, 2013 4:30 pm ET


Carol A. Cox - Senior Vice President of External Affairs & Corporate Communications

Gregory T. Lucier - Chairman and Chief Executive Officer

David F. Hoffmeister - Chief Financial Officer and Senior Vice President

Mark P. Stevenson - President and Chief Operating Officer

Ronald A. Andrews - President of Medical Sciences


Jonathan P. Groberg - Macquarie Research

Tycho W. Peterson - JP Morgan Chase & Co, Research Division

Daniel Brennan - Morgan Stanley, Research Division

Derik De Bruin - BofA Merrill Lynch, Research Division

Amit Bhalla - Citigroup Inc, Research Division

Amanda Murphy - William Blair & Company L.L.C., Research Division

Ross Muken - ISI Group Inc., Research Division

Alison Yang - Barclays Capital, Research Division

David Ferreiro - Oppenheimer & Co. Inc., Research Division

Jeffrey T. Elliott - Robert W. Baird & Co. Incorporated, Research Division

Daniel L. Leonard - Leerink Swann LLC, Research Division

Doug Schenkel - Cowen and Company, LLC, Research Division

Peter Lawson - Mizuho Securities USA Inc., Research Division

Vamil Divan - Crédit Suisse AG, Research Division



Good day, ladies and gentlemen, and welcome to the Life Technologies Corporation Fourth Quarter 2012 Earnings Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded. I would now like to introduce your host for today's conference, Ms. Carol Cox, Head of Investor Relation. Ma'am, you may begin.

Carol A. Cox

Great, thank you, Kay. And good afternoon, everyone. Welcome to Life Technologies Fourth Quarter and Full Year 2012 Earnings Conference Call. We issued our press release today earlier at 1 p.m. Pacific time and posted it on our website at, which is also filed on Form 8-K with the Securities and Exchange Commission. Additionally, we have posted a deck of slides to accompany today's webcast, which may be found in the events and presentations section of the company's investor relations website with our other earnings materials.

Joining me on today's call are Greg Lucier, our Chairman and CEO; David Hoffmeister, our Chief Financial Officer; Mark Stevenson, our Chief Operating Officer; and Ronnie Andrews, our Head of Medical Sciences. They will also be available for Q&A portion of the call. If you have not had a chance to review the earnings release, it can be found on our website, at

Before we get started, I'd just like to remind everyone that our discussion today will include forward-looking statements, including, but not limited to statements about future expectations, plans and prospects for the company, corporate strategy and performance. We believe these statements are based on reasonable assumptions, but actual results may differ materially from those indicated.

Important factors, which could cause actual results to differ materially from those in the forward-looking statements, are detailed in the filings made by the company with the SEC. It is our intent that these forward-looking statements be protected in the safe harbor created by the Private Securities Litigation Reform Act of 1995. Additionally, we will be discussing GAAP and non-GAAP measures. A full reconciliation of the non-GAAP measures to GAAP may be found in today's press release or on our website.

I'll now turn the call over to Greg.

Gregory T. Lucier

Thanks, Carol, and thank you to everyone who is joining us today as we provide an overview of our fourth quarter and full year 2012 results and expectations for 2013.

We started 2012 with a promise to our shareholders to grow our underlying business, invest in growth markets and regions, deliver on balanced capital deployment strategy and introduce innovative new products to serve our customers even better.

Our performance during the year had its challenges, including the weakened macroeconomic environment that affected Life Sciences' industry globally, and uncertainty in NIH funding in the U.S., in particular. But our management team and employees remain focused and were able to deliver against the promises we made.

We introduced game-changing products across all our business groups, expanded further into emerging markets, built the foundation for our Molecular Diagnostics business, and increased our global manufacturing footprint in China, Singapore and Europe, allowing us to be ever more cost competitive.

Now let me turn to the results. For the full year, we delivered revenue and earnings per share growth for the 13th year in a row. Revenue increased 2.2% to $3.8 billion, and our operating margin expanded to 29.2%. Non-GAAP earnings per share increased 7% to $3.98, and our strong free cash flow totaled $662 million, enabling us to invest in growing our business and return $635 million to shareholders through share repurchases.

We finished the year strong with fourth quarter revenue growth at 4.5%, excluding currency. This growth was driven principally by Ion Torrent and our Research Consumables and Bioproduction businesses. Non-GAAP EPS of $1.11 came within the guidance we'd provided and included absorbing a negative $0.03 impact related to the benefit of the 2012 federal R&D tax credit being pushed from Q4 into the first quarter of 2013.

Additionally, we delivered results even though a large order on our Applied Science business moved out of Q4 into 2013. We have been very focused on driving our Consumables business even higher. Our mix of consumables and services is now 85% of our total revenue.

In addition, 2012 is the first year where over half our revenue has been generated outside of the Americas, making us an increasingly global company.

Finally, we have focused over the last 18 months on reducing our exposure to academia and government, which we have been able to reduce by 10%. While this is still an important customer base for us, given the leading edge science taking place in those end markets, we invest more heavily in expanding our footprint in the faster growing hospital and clinical end markets.

Read the rest of this transcript for free on